ABSTRACT
Introduction
Besides being an air pollutant present in the exhaust gas and cigarette smoke, nitric oxide (NO) also functions as the "endothelium derived relaxing factor" (EDRF) in humans. Thus, it is both an endogenous signal molecule produced through biochemical reactions by human cells and an exogenous gas with detrimental effects when inhaled from the polluted ambient air. Also it is a potential carcinogenic molecule owing to its role as a free oxygen radical (1) . NO is synthesized endogenously by a cytosolic enzyme referred to as Nitric Oxide Synthase (NOs), which catalyses NO production through a series of reactions responsible for the conversion of the amino acid L-arginine to citrulline (2) . NO is found in all organ systems. Originally, presence of NO in exhaled air was first reported in 1991 (3) . In healthy individuals, expiration air contains 5 to 10 ppb (particle per billion) of NO, which plays a major role in the pathophysiological processes in the lung. NO is an ideal intracellular and transcellular messenger molecule thanks to its small molecular structure, liphophilicity, and short duration of action (4) .
In asthmatic patients, the increased concentration of exhaled FeNO is a sign of airway inflammation, and in atopic subjects, the increase in FeNO is even more pronounced compared to asthmatics (5) . In allergic rhinitis and asthma, a positive correlation exists between FeNO and serum total IgE levels. In addition, there is a positive correlation between FeNO levels and positive skin test. Normal FeNO ranges defined by ATS/ERS for adults and children are 5-35 ppb and 5-25 ppb, respectively (6) .
However a considerable number of host-related and environmental factors influence FeNO including gender, presence or absence of atopy, diet, physiological status, environmental effects, and the method of measurement. The purpose of our study was to examine the association between FeNO levels and disease control in patients with asthma and to assess the influence of host-related and environmental factors on FeNO measurements.
Materials and Methods

Patient Selection
A total of 40 patients over 18 years of age with ATS (American Thoracic Society) defined asthma and regularly attending to the outpatient unit of our hospital between June 2009 and September 2009 were included in the study (7) . Also 20 healthy individuals were included as the control group. Study subjects and controls were invited to the study center for study assessments at different timepoints. The first assessment timepoint (T1) was scheduled within the low-pollution period between June and September 2009 (based on the 2008 report of Forestry and Environment Agency of Zonguldak province). A basal FeNO measurement was performed in addition to immunologic tests (serum ECP, total IgE), eosinophil counts (in peripheral blood smears), spirometry, and asthma control test (ACT). At the second phase of the study, asthma patients continued their current treatment for two weeks and during that period they were asked to record PEF values twice daily as well as their daily symptoms and short acting beta-mimetic use. Following this two week period (T2) PEF-meter results were retrieved from the patients' self reports and the abovementioned set of assessments were repeated. Also spirometry and ACT were performed.
In the third phase of the study (T3) patients and controls were this time invited to the study center during a highpollution period, i.e. between November and January (based on the 2008 report of Forestry and Environment Agency of Zonguldak province). The same set of assessments as in T1 and T2 were repeated.
Inclusion criteria
• Age over 18
• At least a 3-month history of treated asthma prior to study entry
Exclusion criteria
• Presence of a current asthma attack 
Respiratory Function Tests
Spirometry tests were performed using a Jaeger Masterscreen PFT spirometry device in the respiratory laboratory according to ATS/ERS 2005 guidelines. FeNO assays were performed at an expiratory flow rate of 0.05 L/sec during a single expiratory effort with a portable nitric oxide analyzer (NIOX MINO Airway Inflammation Monitor, Aerocrine AB; Solna, Sweden), again in accordance with ATS/ERS 2005 guidelines (8) . As defined by these guidelines, normal NO range in healthy adults is between 5 and 35 ppm. For the study purposes low, normal, moderately high, and high FeNO levels were defined as follows, respectively: 5 ppb, 5-25 ppb, 25-50 ppb, and > 50 ppb (9).
Asthma Control Test (ACT)
Asthma control test (ACT), a self-administered 5-item questionnaire to identify inadequately controlled asthma, was completed by the patients at the study entry. ACT score varies between a minimum of 5 points and a maximum of 25 points. Following the completion of ACT by the patient, a face to face interview was performed to more accurately define the control level. ACT scores equal to or greater than 20 were considered as "controlled asthma", while scores below 20 were an indication of inadequate control.
Air Pollutants and their Measurement
The major air pollutants emitted by heating systems and industry are particulate matter (PM) and sulphur dioxide (SO 2 ). Particles with an aerodynamic diameter of less than 10 μm bear medical significance as they can enter and accumulate in the respiratory tract. In Turkey, SO 2 and PM measurements are performed by the Agency of Forestry and Environment on a provincial basis. The 2008 air pollution data required for our study (average SO 2 and PM levels) were provided by the Zonguldak Province Agency of Forestry and Environment.
Statistical Analyses
Statistical analyses were performed using SPSS (Version 13.0). The normal distribution of numeric variables was assessed by Kolmogorov-Smirnov test. Descriptive statistics such as mean ± standard deviation was used for numeric data, while categoric data were expressed as number and percentage. Chisquare and Fisher exact chi-square tests were used to evaluate the associations between categoric variables. If parametric test hypothesis was verified, Significance Test between two average values to compare two groups in respect to numerical variations was performed, if it was not verified, MannWhitney U Test was performed. When comparing two asynchronous measurements, in case of verified parametric test hypothesis, Significance Test between two couple, in other case Wilcoxon Matched Two Sample Test was performed. When parameters determined by measurements; variations depend on time was examined by 'Unilateral Variance Analysis'. In repeated measurements, again in case of parameters determined by measurements, variations between groups and variations with respect to time were examined by 'Bilateral Variance Analysis' and Bonferroni Test. Linear relationship between two parameters was examined by Pearson (for datas that demonstrate normal distribution) and Spearman (for datas that don't demonstrate normal distribution). Results were evaluated in 95% confidence bounds and p<0.05 value accepted as significant.
Results
Forty asthmatics (13 male, 27 female; mean age 41.3 ± 11.4 years) and 20 control subjects (10 male, 10 female; mean age 41.3 ± 10.2 years) were included in the study. Current, ex-, and non-smokers comprised 12.5%, 27.5%, and 60% of the patient group and 40%, 20%, and 40% of the control group, respectively. Average height in the corresponding groups was 164 ± 0.06 and 172 ± 0.07 cm and BMI was 28.2 ± 6.2 and 27.4 ± 4.5 kg/m2. Fifty percent of the asthma patients had atopy, with no atopy in control subjects. Asthma medications used by the patients were as follows: rapid acting beta-2 agonist only on an as-needed basis in three patients; low dose inhaled corticosteroids (ICS) only in one patient; LABA only in one patient; LABA and moderate dose ICS in nine patients; LTRA only in 15 patients; LTRA, LABA and moderate dose ICS in 11 patients.
At timepoint T1, FeNO levels were lower in current smokers in both groups, i.e. asthmatics and controls, although the difference was not statistically significant (p=0.593 for the patient group; p=0.285 for the controls). Also no significant correlations were found between simultaneous FeNO measurements and baseline FEV1%, absolute FEV1, and FEF 25-75% values (p > 0.05). Twicedaily PEF measurements at morning and evening hours were performed for 14 days by the patients using PEFmeters starting from T1. Among 40 patients, PEF variability was higher than 20% in two, and lower than 20% in the remaining 38, with an average PEF variability of 9.55 ± 5.2.
In terms of the association between PEF variability and ACT, ECP, total IgE, eosinophilia, and FeNO levels at T1, a negative correlation was observed between ACT and PEF variability, with no other significant associations . At T2, no significant correlations was found for the same parameters (p > 0.05 for each). Average ACT for the patient group at T1, T2 and T3 were 23.05 ± 2.24, 23.6 ± 1.56, and 23.8 ± 1.42, respectively, with a significant change in this parameter from T1 through T2 and T3 (p 0.027). Further analyses showed that the significance resulted from the difference between T1 and T2, and no significant increase was found between T2 and T3 ( Figure 1 ). Baseline (T1) ACT levels were used to categorize patients into the following three groups: undercontrolled, ACT < 20; partially controlled, ACT between 20 and 24; and well controlled, ACT = 25. A comparison of the baseline FeNO levels in these three groups showed a significant difference (p < 0.001) mainly resulting from the ACT value in the undercontrolled group. Sensitivity and specificity of a cut-off point of 25 ppb for FeNO to indicate asthma control were 72.2% and 75%, respectively, with a PPV of 96.2% and NPV of 23%. The corresponding figures for a cut-off of 50 ppb were 97.2%, 75%, 97.2%, and 75%, respectively.
A comparison at T1 of serum total IgE, ECP, exposure level to air pollutants (SO 2 , PM), and FeNO levels showed a significant difference in total IgE, ECP and FeNO between the groups (p = 0.03, p = 0.25, p < 0.01, respectively), while no significant differences were found for PM and SO 2 (p = 0.171 and p = 0.630, respectively) ( Table 1) .
A comparison at T3 of serum total IgE, ECP, exposure level to air pollutants (SO 2 , PM), and FeNO levels among patients and controls showed a significant difference in total IgE and FeNO (p = 0.013 and p < 0.001, respectively), while no significant differences were found for exposure to air pollutants (PM and SO2) and ECP (p = 0.170, p = 0.83, and p = 0.183, respectively).
In the patient group, a comparison between T1 and T3 for the same parameters showed a statistically significant change for SO 2 and PM exposure (p=0.001 for both). Also in the control group, a significant change has been found to occur in FeNO and exposure to air pollutants (SO 2 and PM) from T1 to T3 (p=0.02, p=0.001, and p=0.001, respectively).
Discussion
Endogenous nitric oxide plays a significant role in the pathophysiology of the respiratory diseases and in the physiological regulation of airway function (10, 11, and 12) . Nitric oxide also plays a major role in the asthma pathogenesis through its effects on bronchodilatation, bronchial hyperreactivity, and airway inflammation (13) . Previous studies suggested an independent correlation between height, gender and FeNO concentrations (14, 15) . In the present study, the patient and control groups were not significantly different in terms of gender, age, and BMI, while there was a significant height difference (p=0.001). Despite this finding, no significant association between height and FeNO was observed. A within group assesment for patient and control groups showed no association between age, height, BMI, and FeNO levels. Similarly, in both groups, there were no gender differences in FeNO levels. Chronic cigarette use was previously shown to decrease FeNO levels. Also, cigarette smoking within 1 hour of FeNO measurement is known to be associated with acute decrease in FeNO concentrations (8, 16) . In our study, despite lower FeNO levels in ex-smokers in both groups, the difference was not statistically significant. Using daily PEF-meter records (for two week), ACT, and FeNO a total of 45 patients with complete control of asthma (ACT = 25) were identified. A comparison between patients with or without complete asthma control showed a negative correlation between PEF-meter records, FeNO levels and ACT (17) . In our study patients were divided into the following two groups based on the baseline ACT: patients with controlled asthma (ACT ≥ 20) and patients with uncontrolled asthma (ACT <20). Based on the baseline ACT and FeNO assessments, a total of 26 patients with completely stable asthma were identified who had both an ACT equal to or greater than 20 and FeNO below 25 ppb. In a single case, ACT was below 20 despite low FeNO. This finding was probably due to the presence of other non-inflammatory causes of inadequate asthma control such as untreated A significant change was observed through different timepoints of the study (p < 0.027). ACT values improved significantly with treatment, with a parallel decrease in FeNO levels, although the latter change was not statistically significant.
Although air pollution affects the health status of asthma patients, its role in the development of asthma is not clear. A cohort study from Norway with a follow up from birth found no association between bronchial obstruction occurring within the first two years of life and outdoor air pollution (18). On the other hand, Steerenberg et al. observed a direct relationship between FeNO levels in children and nitrogen dioxide, NO, black fume, and particles smaller than 10 μm (19) . Another study showed a correlation between FeNO levels and concentration of outdoor, not indoor, particulate matter, supporting the key role of outdoor air pollution in airway inflammation (20) . In a laboratory study, Pietropaoli et al. failed to observe a significant change in NO levels with increasing exposure to carbon particles in asthma patients and healthy individuals. A clear explanation could not be made for this seemingly contradictory finding, although it may be associated with the difference between real life chronic exposure in epidemiologic studies and acute exposure in the laboratory environment (21) . In our study, we could not detect a statistically significant relationship between SO2, PM, and FeNO (p > 0.05) at T1 and T3 both in the patient and control group. However, in conjunction with the dramatic increase in SO2 and PM due to increased air pollution in the winter season, a significant increase in FeNO was found in the control group at T1 and T3 (p=0.02). On the other hand, the difference in FeNO concentrations in the patient group was not significant despite the same increase in SO 2 and PM (p=0.405). The latter finding may be associated with the long term use of efficient doses of anti-inflammatory medication in asthma patients and probably higher levels of exposure to air pollution among healthy subjects. A comparison was not possible in terms of these theoretical assumptions due to the lack of literature data.
In conclusion our results suggest that atopy should be evaluated in asthma patients with high FeNO levels; FeNO alone cannot be utilized to monitor disease control in adult patients with stable asthma; a FeNO < 25 ppb has a high predictive value for identifying asthma control; FeNO levels are not influenced by host-related factors and air pollution in asthma patients; and although FeNO is not influenced by host factors among healthy subjects, increasing air pollution in winter season may have a more pronounced effect in these individuals.
